Aradigm is an emerging specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases by pulmonologists. The Company has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and smoking cessation.

Company Growth (employees)
Type
Public
HQ
Hayward, US
Size (employees)
23 (est)+44%
Aradigm is headquartered in Hayward, US

Key People/Management at Aradigm

Igor Gonda

Igor Gonda

President & Chief Executive Officer
Nancy Pecota

Nancy Pecota

Chief Financial Officer

Aradigm Office Locations

Aradigm has an office in Hayward
Hayward, US (HQ)
3929 Point Eden Way

Aradigm Financials and Metrics

Aradigm Financials

Aradigm's revenue was reported to be $195 k in FY, 2016
USD

Revenue (Q3, 2017)

2.7 m

EBIT (Q3, 2017)

(2.9 m)

Market capitalization (13-Dec-2017)

82.2 m

Cash (30-Sep-2017)

12.6 m
Aradigm's current market capitalization is $82.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016

Revenue

9.7 m33.6 m23.4 m195 k

Revenue growth, %

245%(30%)(99%)

R&D expense

24.4 m

General and administrative expense

5.8 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Revenue

4.6 m6.6 m12.2 m6.6 m8.8 m10 m4.7 m6 k14 k50 k1.7 m7.7 m2.7 m

R&D expense

1.6 m5.8 m11.7 m6 m8.4 m9.8 m8.9 m6.5 m6.2 m5.8 m2.8 m3.8 m

General and administrative expense

1.5 m1.7 m1.9 m1.4 m1.5 m1.3 m1.3 m1.6 m1.4 m1.5 m1.7 m1.9 m

Operating expense total

19 m7.5 m13.6 m7.5 m9.9 m11.1 m10.2 m8.1 m7.6 m7.3 m4.5 m5.7 m5.7 m
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

48.1 m48 m31.5 m22.6 m

Accounts Receivable

499.1 m

Current Assets

49.7 m50.5 m35.2 m24.8 m

PP&E

400 k502 k299 k253 k
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017

Cash

38.7 m41.7 m50.3 m48.5 m48.6 m49 m40 m22.4 m31.2 m28.5 m17.2 m12 m12.6 m

Current Assets

53.3 m45.9 m52.6 m49.8 m50.8 m50.9 m41.6 m26.5 m35.7 m32 m19.7 m13 m13.6 m

PP&E

461 k493 k539 k582 k416 k353 k325 k310 k282 k278 k225 k227 k

Total Assets

54.2 m46.5 m56.1 m53.4 m54.1 m54.1 m44.8 m26.8 m36 m32.3 m19.9 m13.2 m14 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (21.6 m)4.7 m(17.2 m)(32.9 m)

    Depreciation and Amortization

    370 k310 k203 k121 k

    Accounts Payable

    289 k2.1 m(917 k)(1.1 m)

    Cash From Operating Activities

    264 k107 k(16.7 m)(28.5 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (14.9 m)7.8 m(1.4 m)(914 k)(1.1 m)(5.5 m)

    Accounts Payable

    4 m1.4 m2 m3 m1.9 m2.5 m1.2 m956 k532 k980 k
      USDY, 2017

      Revenue/Employee

      118.6 k

      Financial Leverage

      -1.5 x
      Show all financial metrics

      Aradigm Operating Metrics

      FY, 2014FY, 2015FY, 2016

      Patents Pending

      352749

      Patents Issued

      828280
      Show all operating metrics

      Aradigm Market Value History

      Aradigm's Web-traffic and Trends

      Aradigm Company Life and Culture

      You may also be interested in